Eli Lilly (LLY) Price Target Raised to $1,400 Following Q1 Results
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowEli Lilly and Company (LLY) received a price target increase to $1,400 from $1,350 by Barclays following strong first-quarter results. Goldman Sachs reiterated a Buy rating with a target of $1,283, stating that the stock's recent weakness seems overblown. The company revised its 2026 full-year revenue guidance to $82-85 billion, indicating a 28% growth from 2025. Additionally, LLY's non-GAAP EPS is estimated between $35.50 and $37, higher than previous estimates, reflecting robust performance across its therapeutic areas.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- Novo Nordisk (NVO) high-dose Wegovy shows 27.7% weight loss
- Pfizer (PFE) Stock Down Over 50% from 2021 High Amid Challenges
- Eli Lilly (LLY) Reports 56% Revenue Growth, Raises 2026 Outlook
- Premarket Stocks: Meta, Eli Lilly, Caterpillar and Amazon Update
- Eli Lilly (LLY) Reports Q1 Earnings, Raises 2026 Revenue Outlook by $2B
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
